Burrill Report: Biotech Innovation Gets the Cash
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
Month: November 2009
Adeona’s Experimental RA Drug Does Well in Phase II Trial
Adeona Pharmaceuticals, a developer of medications for CNS and autoimmune diseases, announced data from a Phase II clinical trial of its rheumatoid arthritis drug candidate.
NicOx Reports Positive Data for Cholesterol Drug
NicOx announced that NCX 6560, its drug candidate for high cholesterol, met its primary and secondary endpoints in a Phase Ib man-in study.
Ironwood Receives $75M from Astellas for IBS Drug
The Cambridge, Mass.-based company has signed a $75 million deal with Astella Pharmaceuticals to market Ironwood’s IBS drug in Asia.
Avanir Shares Rise on Zenvia Trial Data
Avanir, a pharmaceutical company developing treatments for CNS disorders and inflammatory diseases, announced that its multiple sclerosis drug Zenvia met its goal in a six-month clinical trial.
ProtoxPresents Data, Awaits Key Results for PRX302
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
Bioniche Receives $6M Milestone Payment for Bladder Cancer Drug
Bioniche Life Sciences has received its first milestone payment of $6 million from Endo Pharmaceuticals for its experimental bladder cancer drug.
Guided Therapeutics Study Reveals Cervical Screening Shortcomings
A clinical trial by Guided Therapeutics (GT), a biotechnology company specializing in women’s health, found that current screening methods for cervical disease missed the disease nearly a third of the time.
GenVec Receives Orphan Drug Designation, $22M Development Deal
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
UNICEF and WHO Launch Global Plan Against Pneumonia
The World Health Organization (WHO) and UNICEF are kicking off a comprehensive plan to fight the world’s leading child killer.